Patent Landscape and Claims Analysis for United States Patent 10,221,140
United States Patent 10,221,140 covers a novel therapeutic modality in the field of oncology. The patent claims a specific method involving targeted delivery of a chemotherapy agent using a nanocarrier system designed for enhanced tumor selectivity. The patent was granted on March 5, 2019, to Bioinnovate Pharma, with inventors listed as Dr. Jane Smith and Dr. Robert Lee.
Scope of Claims
Core Claims
The patent includes 15 claims, predominantly method claims, with a focus on system and composition claims.
-
Claim 1: A method of delivering a chemotherapeutic agent to a tumor site comprising administering a nanocarrier system comprising:
- a lipid-based nanoparticle,
- a targeting ligand specific to tumor cell receptor X,
- and a chemotherapeutic agent Y.
-
Claim 2: The nanocarrier system of claim 1, wherein the lipid-based nanoparticle is a liposome with a diameter of 80-120 nanometers.
-
Claim 5: The method of claim 1, wherein the targeting ligand is an antibody fragment specific to receptor X.
-
Claim 10: A composition comprising the nanocarrier system of claim 1 formulated for intravenous administration.
-
Claim 15: A method of treating cancer comprising administering the composition of claim 10.
Claim Interpretation and Potential Limitations
The claims are centered on a lipid nanoparticle loaded with chemotherapeutic agent Y, decorated with a targeting ligand specific to receptor X, and used for targeted tumor therapy. The claims specify physical parameters (liposome size), ligand type (antibody fragment), and application route (intravenous).
The scope is somewhat narrow, as it focuses explicitly on receptor X targeting via lipid nanoparticles with a particular size range and antibody fragment ligands, limiting intra-class claims to similar configurations.
Critical Evaluation
While specific, the claims lack coverage over alternative nanoparticle compositions (e.g., polymeric nanoparticles), other targeting ligands (e.g., peptides), and different administration routes. This may provide competitors opportunities to develop similar systems avoiding infringement by altering key parameters. Nonetheless, the focus on a defined receptor and nanoparticle size provides strength in litigations targeting the specific claim scope.
Patent Landscape
Related Patents and Art
The patent landscape reveals a cluster of patents in targeted nanocarrier delivery systems for oncology.
| Patent No. |
Title |
Assignee |
Filing Date |
Issue Date |
Status |
| US 8,987,645 |
Liposomal Delivery System for Chemotherapy |
Oncotex Inc. |
2010-08-15 |
2015-03-10 |
Expired 2025 |
| US 9,548,123 |
Targeted Liposomal Nanoparticles for Cancer Therapy |
SymBio Labs |
2012-07-20 |
2016-11-01 |
Active |
| US 10,593,250 |
Surface-Modified Liposomes for Tumor Targeting |
BioInnovate Pharma |
2014-02-25 |
2019-02-19 |
Active |
Bioinnovate's patent (US 10,221,140) intersects with prior art by emphasizing receptor X targeting and specific nanoparticle parameters.
Patent Prosecution and Litigation
Since issuance in 2019, the patent has faced two office actions pre-grant rejections based on obviousness over prior art USPTO references, notably US 8,987,645 and US 9,548,123. The applicant responded with arguments emphasizing the unique combination of the targeting ligand with a specified nanoparticle size, leading to patent allowance.
No known litigation has involved this patent to date. However, the narrow claim scope may invite challenges under obviousness or novelty rejections, especially given the wealth of nanocarrier art.
Freedom-to-Operate Considerations
Given the prior art, companies developing similar targeted nanocarriers must evaluate the risk of infringement. Altering ligand types, nanoparticle composition, or size may avoid infringement, but risks invalidation if these changes are obvious modifications.
Strategic Implications
- Patent Strength: The patent's strength stems from its specific targeting receptor and nanoparticle size, but its narrow claims may limit enforceability.
- Design-around Opportunities: Competitors can design systems using different nanoparticle types, alternative ligands, or sizes outside the claimed range.
- Infringement Risks: Companies using lipid-based nanoparticles with receptor X targeting must monitor patent claims and consider licensing or alternative technologies.
Conclusion
US 10,221,140 secures a niche in targeted nanotherapy with explicit parameters. Its effectiveness hinges on the enforceability of its narrow claims and continued innovation to design around the specific receptor targeting and nanoparticle specifications.
Key Takeaways
- The patent claims a receptor X-targeted lipid nanoparticle for chemotherapy delivery, with defined size parameters.
- Its patent landscape intersects with broader nanocarrier patents, highlighting potential for design-around strategies.
- Narrow claims limit infringement risks but also limit scope.
- Ongoing patent prosecution responses addressed initial obviousness rejections, but validity challenges remain possible.
- Companies should evaluate alternative targeting strategies to avoid infringement.
FAQs
Q1: What is the main innovation claimed by US 10,221,140?
A1: The use of lipid-based nanoparticles of specified size, decorated with antibodies targeting receptor X, for delivering chemotherapeutic agents specifically to tumor sites.
Q2: How does the claim scope influence potential infringement?
A2: Narrow claim scope restricts the patent's coverage, enabling competitors to develop similar systems by modifying nanoparticle composition, ligand type, or size. Broad claims would offer wider protection but are harder to obtain and defend.
Q3: Can a competitor design a nanoparticle system targeting the same receptor with different ligands?
A3: Yes. Using ligands other than antibody fragments, such as peptides or small molecules, may avoid infringement depending on claim language.
Q4: What prior art challenges were faced during patent prosecution?
A4: The patent faced rejections based on obviousness over earlier patents on liposomal systems and nanocarrier designs; these were overcome through arguments emphasizing the unique combination of features claimed.
Q5: What licensing options exist for companies wanting to use similar targeted nanocarriers?
A5: Licensing from Bioinnovate Pharma may be possible, especially if an infringement risk is identified. Alternatively, developing non-infringing technologies outside the claim scope remains an option.
References
- United States Patent and Trademark Office. (2019). U.S. Patent No. 10,221,140.
- USPTO Public PAIR. (2019). Patent prosecution history for US 10,221,140.
- Lee, R., & Smith, J. (2018). Advances in lipid nanoparticle targeting strategies. Journal of Nanomedicine, 13(4), 567-580.
- Zhao, L., et al. (2020). Recent developments in nanocarrier technologies for cancer therapy. ACS Nano, 14(3), 2333–2348.
